Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765

A Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of VX-765 in Subjects With Chronic Plaque Psoriasis Requiring Systemic Therapy

To evaluate the safety and tolerability of VX-765 in subjects with chronic plaque psoriasis treated for 28 days.

Inclusion Criteria:

• Diagnosed with chronic plaque psoriasis for at least 6 months
• Prior systemic therapy

Exclusion Criteria:

• Current or prior history of illness precluding use of immunomodulatory therapy.